XPR – Lifestyle Demo
Author:
InflaRx N.V.
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
March 19, 2026
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
March 18, 2026
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
March 13, 2026
InflaRx to Report Full Year 2025 Results on March 19, 2026
March 12, 2026